Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity

Joseph Finkelstein, Eunme Cha, Steven M Scharf, Joseph Finkelstein, Eunme Cha, Steven M Scharf

Abstract

Rationale: Recent studies described association between chronic obstructive pulmonary disease (COPD) and increased risk of cardiovascular diseases (CVD). In their analysis none of these studies accounted for sociodemographic factors, health behaviors, and patient comorbidities simultaneously.

Objective: To study whether COPD diagnosis is an independent risk factor for CVD.

Methods: Subjects aged 40 years and older (N = 18,342) from the sample adult file of the 2002 National Health Interview Survey (NHIS) were included in the analysis. Chi-squared tests and odds ratios (OR) were utilized to compare the data. Multiple logistic regression was employed to analyze the association between COPD and CVD with simultaneous control for sociodemographic factors (age, gender, race, marital status, education, income), health behaviors (tobacco use, alcohol consumption, physical activity), and patient comorbidities (diabetes, hypertension, high cholesterol, and obesity). The analysis employed NHIS sampling weights to generate data representative of the entire US population.

Results: The COPD population had increased prevalence of CVD (56.5% vs 25.6%; P < 0.0001). Adjusted logistic regression showed that COPD patients (N = 958) were at higher risk of having coronary heart disease (OR = 2.0, 95% CI: 1.5-2.5), angina (OR = 2.1, 95% CI: 1.6-2.7), myocardial infarction (OR = 2.2, 95% CI: 1.7-2.8), stroke (OR = 1.5, 95% CI: 1.1-2.1), congestive heart failure (OR = 3.9, 95% CI: 2.8-5.5), poor circulation in lower extremities (OR = 2.5, 95% CI: 2.0-3.0), and arrhythmia (OR = 2.4, 95% CI: 2.0-2.8). Overall, the presence of COPD increased the odds of having CVD by a factor of 2.7 (95% CI: 2.3-3.2).

Conclusions: These findings support the conclusion that COPD is an independent risk factor for CVD.

Keywords: cardiovascular disease; case-control study; chronic obstructive pulmonary disease; population-based analysis; risk factors.

References

    1. Petty TL. Definition, epidemiology, course and prognosis of COPD. Clin Cornerstone. 2003;5:1–10.
    1. Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993: An analysis using multiple-cause mortality data. Am J Respir Crit Care Med. 1997;156:814–818.
    1. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005;128:2005–2011.
    1. Pope CA, 3rd, Burnett RT, Thurston GD, et al. Cardiovascular mortality and long-term exposure to particulate air pollution. Epidemiological evidence of general pathophysiological pathways of disease. Circulation. 2004;109:71–77.
    1. Sin DD, Man SFP. Chronic obstructive pulmonary disease: A novel risk factor for cardiovascular disease. Can J Physiol Pharmacol. 2005;83:8–13.
    1. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70.
    1. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099–2107.
    1. Sidney S, Sorel M, Quesenberry CP, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128:2068–2075.
    1. Rennard SI. Clinical approach to patients with chronic obstructive pulmonary disease and cardiovascular disease. Proc Am Thorac Soc. 2005;2:94–100.
    1. Hunninghake DB. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):44–49.
    1. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347–360.
    1. Anthonisen NR, Connett JE, Enright PL, Manfreda J, Lung Health Study Research Group Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166:333–339.
    1. Engström G, Hedblad B, Janzon L, Valind S. Respiratory decline in smokers and ex-smokers – an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk. 2000;7:267–272.
    1. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127:1952–1959.
    1. National Health Interview Survey [machine-readable data files] 2002. Available from Accessed on August 1, 2009.
    1. National Health Interview Survey [machine-readable documentation] 2002. Available from Accessed on August 1, 2009.
    1. Giles WH, Croft JB, Keenan NL, Lane MJ, Wheeler FC. The validity of self-reported hypertension and correlates of hypertension awareness among blacks and whites within the stroke belt. Am J Prev Med. 1995;11:163–169.
    1. Vargas CM, Burt VL, Gillum RF, Pamuk ER. Validity of self-reported hypertension in the National Health and Nutrition Examination Survey III, 1988–1991. Prev Med. 1997;26:678–685.
    1. Bartlett DL, Ezzati-Rice TM, Stokley S, Zhao Z. Comparison of NIS and NHIS/NIPRCS vaccination coverage estimates. National Immunization Survey. National Health Interview Survey/National Immunization Provider Record Check Study. Am J Prev Med. 2001;20(4 Suppl):25–27.
    1. Yabroff KR, Gordis L. Assessment of a national health interview survey-based method of measuring community socioeconomic status. Ann Epidemiol. 2003;13:721–726.
    1. National Health Interview Survey: research for the 1995–2004 redesign. Vital Health Stat 2. 1999;(126):1–119.
    1. Design and estimation for the National Health Interview Survey, 1995–2004. Vital Health Stat 2. 2000;(130):1–31.
    1. An AB. Performing Logistic Regression on Survey Data with the New SURVEYLOGISTIC Procedure. Paper 258–27. Proceedings of the 27th Annual SAS Users Group International Conference (SUGI 27); Orlando, FL. April 14–17; 2002. pp. 1–9.
    1. Breslow NE, Day NE. Statistical methods in cancer research. Volume I. The analysis of case-control studies. IARC Sci Publ. 1980;32:5–338.
    1. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2:8–11.
    1. Engstrom G, Hedblad B, Janzon L. Reduced lung function predicts fatality in future cardiac events. A population-based sutdy. J Intern Med. 2006;260:560–567.
    1. Jousilahti P, Vartiainen E. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet. 1996;348:567–572.
    1. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128:2640–2646.
    1. Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol. 2007;99:636–641.
    1. Schroeder EB, Welch VL, Couper D, et al. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2003;158:1171–1181.
    1. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.
    1. Stavem K, Aaser E, Sandvik L, et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J. 2005;25:618–625.
    1. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574–580.
    1. Cohen RI, Marzouk K, Berkoski P, O’Donnell CP, Polotsky VY, Scharf SM. Body composition and resting energy expenditure in clinically stable, non-weight-losing patients with severe emphysema. Chest. 2003;124:1365–1372.
    1. Suissa S, Hemmelgarn B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med. 1996;154:1598–1602.
    1. Kiely DG, Cargill RI, Grove A, Struthers AD, Lipworth BJ. Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Thorax. 1995;50:1062–1066.
    1. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med. 2000;161:827–830.
    1. Suissa S, Assimes T, Ernst P. Inhaled short acting β agonist use in COPD and the risk of acute myocardial infarction. Thorax. 2003;58:43–46.
    1. Truelsen T, Prescott E, Lange P, Schnohr P, Boysen G. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study. Int J Epidemiol. 2001;30(1):145–151.
    1. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450.
    1. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149(6):380–390.
    1. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD.Cardiovascular Events Associated With Ipratropium Bromide in COPD Chest 2009April10[Epub ahead of print].
    1. Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis. 2008;3(1):163–169.
    1. Rana JS, Mittleman MA, Sheikh J, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care. 2004;27:2478–2484.
    1. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128:3618–3624.
    1. Stein PK, Nelson P, Rottman JN, et al. Heart rate variability reflects severity of COPD in PiZ alpha1-antitrypsin deficiency. Chest. 1998;113:327–333.
    1. Newman AB, Naydeck BL, Sutton-Tyrrell K, Feldman A, Edmundowicz D, Kuller LH. Coronary artery calcification in older adults to age 99: prevalence and risk factors. Circulation. 2001;104:2679–2684.
    1. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:1259–1265.
    1. Schols AM, Fredrix EW, Soeters PB, Westerterp KR, Wouters EF. Resting energy expenditure in patients with chronic obstructive pulmonary disease. Am J Clin Nutr. 1991;54:983–987.
    1. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007;175:458–463.
    1. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 Suppl):121S–126S.
    1. Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J. 2003;21(Suppl 41):29S–35S.
    1. Malarcher AM, Schulman J, Epstein LA, et al. Methodological issues in estimating smoking-attributable mortality in the United States. Am J Epidemiol. 2000;152(6):573–584.
    1. Egede LE, Zheng D. Racial/ethnic differences in influenza vaccination coverage in high-risk adults. Am J Public Health. 2003;93(12):2074–2078.
    1. Egede LE. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry. 2007;29(5):409–416.
    1. Pleis JR, Barnes PM. A comparison of respiratory conditions between multiple race adults and their single race counterparts: an analysis based on American Indian/Alaska Native and white adults. Ethn Health. 2008;13(5):399–415.
    1. Harlow SD, Linet MS. Agreement between questionnaire data and medical records. The evidence for accuracy of recall. Am J Epidemiol. 1989;129(2):233–248.
    1. Leikauf J, Federman AD. Comparisons of self-reported and chart-identified chronic diseases in inner-city seniors. J Am Geriatr Soc. 2009;57(7):1219–1225.
    1. Global Initiative for Chronic Obstructive Lung Disease[machine-readable data files], 2008. Available from Accessed August 1, 2009.
    1. Davies JC, Alton EW. Monitoring respiratory disease severity in cystic fibrosis. Respir Care. 2009;54(5):606–617.
    1. Altintas A, Demir T, Ikitimur HD, Yildirim N. Pulmonary function in multiple sclerosis without any respiratory complaints. Clin Neurol Neurosurg. 2007;109(3):242–246.
    1. Yeh HC, Punjabi NM, Wang NY, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2008;31(4):741–746.
    1. Steele RM, Finucane FM, Griffin SJ, Wareham NJ, Ekelund U. Obesity is associated with altered lung function independently of physical activity and fitness. Obesity. 2009;17(3):578–584.
    1. Moayyeri A, Bingham SA, Luben RN, Wareham NJ, Khaw KT. Respiratory function as a marker of bone health and fracture risk in an older population. J Bone Miner Res. 2009;24(5):956–963.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel